Fluoxetine (Prozac)
What studies of Fluoxetine (Prozac) found
At a glance, by condition
ME/CFS: D Little or no difference
Based on the strongest evidence, the placebo trial and studies with no comparison group and the randomised trial and randomised trials (very low certainty): 4 of 7 findings are D.
9 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Studies found little or no difference with Fluoxetine (Prozac) for ME/CFS. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- CMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- Fluoxetine (Prozac) · ME/CFS is hereDLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
ME/CFS
Symptoms
Sleep2 studies · 126 people took Fluoxetine (Prozac) Mixed results C
Why this grade: Mixed results, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (156 in all); the studies disagree; randomised trials found mixed results.
Randomised trials2 studies · 156 people with results
Studies disagree about sleep.
Studies disagree about whether fluoxetine (Prozac) helps sleep. Mixed results · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (156 in all)
- The studies disagree
See the 2 studies
-
Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. (1996)
- People in the study
- 107 randomised · 96 analysed
- Dose
- 20 mg, once a day
- Outcome
- sleep disturbances symptom checklist
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Low
-
- People in the study
- 60 randomised
- Dose
- 20 mg, once per day
- Outcome
- subjective sleep quality Pittsburgh sleep quality index
- Effect
- worse
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
Cognition (brain fog)1 study · 96 people took Fluoxetine (Prozac) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 96 people found no clear difference; a small benefit can't be ruled out.
The placebo trial107 randomised · 96 analysed · 8 weeks · 20 mg, once a day
No clear difference in cognition (brain fog).
The evidence is very uncertain about the effect of fluoxetine (Prozac) on cognition (brain fog) in ME/CFS. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 96 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. (1996)
- People in the study
- 107 randomised · 96 analysed
- Dose
- 20 mg, once a day
- Outcome
- cognitions modified pain cognition list
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Low
Depression1 study · 96 people took Fluoxetine (Prozac) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 96 people found no clear difference; a small benefit can't be ruled out.
The placebo trial107 randomised · 96 analysed · 8 weeks · 20 mg, once a day
No clear difference in depression.
The evidence is very uncertain about the effect of fluoxetine (Prozac) on depression in ME/CFS. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 96 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. (1996)
- People in the study
- 107 randomised · 96 analysed
- Dose
- 20 mg, once a day
- Outcome
- depression Beck depression inventory
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Low
Low mood or anxiety1 study · 40 people took Fluoxetine (Prozac) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 40 people found no clear difference; a small benefit can't be ruled out; effect size 0.23 (small).
The randomised trial40 randomised · 12 weeks · 20 mg, uid
No clear difference in low mood or anxiety.
The evidence is very uncertain about the effect of fluoxetine (Prozac) on low mood or anxiety in ME/CFS. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 40 people found no clear difference; a small benefit can't be ruled out
- Effect size 0.23 (small)
How big was the difference?
0.23, small. The effect size compares Fluoxetine (Prozac) with amisulpride group.
See the 1 study
-
Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study. (2011)
- People in the study
- 40 randomised
- Dose
- 20 mg, uid
- Outcome
- HADS-D Hospital Anxiety and Depression Scale
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
Fatigue3 studies · 166 people took Fluoxetine (Prozac) Uncertain –
Why this grade: Uncertain, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (196 in all); the studies disagree; effect size 1.92 (large); helped less than amisulpride group, an active treatment; not a sign of harm.
Randomised trials3 studies · 196 people with results
Fatigue improved less than with the comparison treatment.
Fluoxetine (Prozac) helped fatigue less than amisulpride group in the one comparison. Uncertain · very low certainty –
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (196 in all)
- The studies disagree
- Effect size 1.92 (large)
- Helped less than amisulpride group, an active treatment; not a sign of harm
How big was the difference?
1.92, large. The effect size compares Fluoxetine (Prozac) with placebo.
See the 3 studies
-
Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. (1996)
- People in the study
- 107 randomised · 96 analysed
- Dose
- 20 mg, once a day
- Outcome
- subjective fatigue checklist individual strength
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Low
-
Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study. (2011)
- People in the study
- 40 randomised
- Dose
- 20 mg, uid
- Outcome
- FSS Krupp Fatigue Severity Scale
- Effect
- worse
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
-
- People in the study
- 60 randomised
- Dose
- 20 mg, once per day
- Outcome
- value of physical fatigue Fatigue scale-14
- Effect
- worse
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
Pain1 study · 40 people took Fluoxetine (Prozac) Uncertain –
Why this grade: Uncertain, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (40 in all); effect size 1.25 (large); helped less than amisulpride group, an active treatment; not a sign of harm.
The randomised trial40 randomised · 12 weeks · 20 mg, uid
Pain improved less than with the comparison treatment.
Fluoxetine (Prozac) helped pain less than amisulpride group in the one comparison. Uncertain · very low certainty –
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (40 in all)
- Effect size 1.25 (large)
- Helped less than amisulpride group, an active treatment; not a sign of harm
How big was the difference?
1.25, large. The effect size compares Fluoxetine (Prozac) with amisulpride group.
See the 1 study
-
Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study. (2011)
- People in the study
- 40 randomised
- Dose
- 20 mg, uid
- Outcome
- VAS-pain visual analog scale
- Effect
- worse
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
Daily life and health overall
Daily functioning2 studies · 97 people took Fluoxetine (Prozac) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 96 people found no clear difference; a small benefit can't be ruled out.
The placebo trial107 randomised · 96 analysed · 8 weeks · 20 mg, once a day
No clear difference in daily functioning.
The evidence is very uncertain about the effect of fluoxetine (Prozac) on daily functioning in ME/CFS. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 96 people found no clear difference; a small benefit can't be ruled out
Studies with no comparison group1 in the study · nearly two years after initial presentation · 20mg daily, for 10 weeks (few people)
Daily functioning improved.
The evidence is very uncertain about the effect of fluoxetine (Prozac) on daily functioning in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 2 studies
-
Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. (1996)
- People in the study
- 107 randomised · 96 analysed
- Dose
- 20 mg, once a day
- Outcome
- functional impairment sickness impact profile
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Low
-
Pervasive refusal syndrome. (2012)
- People in the study
- 1 in the study
- Dose
- 20mg daily, for 10 weeks
- Outcome
- mobility
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms4 studies · 167 people took Fluoxetine (Prozac) Uncertain –
Why this grade: Uncertain, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (196 in all); the studies disagree; effect size 1.63 (large); helped less than amisulpride group, an active treatment; not a sign of harm.
Randomised trials3 studies · 196 people with results
Overall symptoms improved less than with the comparison treatment.
Fluoxetine (Prozac) helped overall symptoms less than amisulpride group in the one comparison. Uncertain · very low certainty –
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (196 in all)
- The studies disagree
- Effect size 1.63 (large)
- Helped less than amisulpride group, an active treatment; not a sign of harm
How big was the difference?
1.63, large. The effect size compares Fluoxetine (Prozac) with amisulpride group.
Studies with no comparison group1 in the study · nearly two years after initial presentation · 20mg daily, for 10 weeks (few people)
Overall symptoms improved.
The evidence is very uncertain about the effect of fluoxetine (Prozac) on overall symptoms in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 4 studies
-
Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study. (2011)
- People in the study
- 40 randomised
- Dose
- 20 mg, uid
- Outcome
- CGI-S Clinical Global Impression Severity
- Effect
- worse
- Risk of bias
RoB 2: Some concerns
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
- People in the study
- 60 randomised
- Dose
- 20 mg, once per day
- Outcome
- total effective rate
- Effect
- worse
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
-
Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. (1996)
- People in the study
- 107 randomised · 96 analysed
- Dose
- 20 mg, once a day
- Outcome
- self-reported change at follow-up testing
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
Pervasive refusal syndrome. (2012)
- People in the study
- 1 in the study
- Dose
- 20mg daily, for 10 weeks
- Outcome
- communication, eating, dark glasses, tolerance of sound
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Quality of life1 study · 40 people took Fluoxetine (Prozac) Uncertain –
Why this grade: Uncertain, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (40 in all); effect size 2.62 (large); helped less than amisulpride group, an active treatment; not a sign of harm.
The randomised trial40 randomised · 12 weeks · 20 mg, uid
Quality of life improved less than with the comparison treatment.
Fluoxetine (Prozac) helped quality of life less than amisulpride group in the one comparison. Uncertain · very low certainty –
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (40 in all)
- Effect size 2.62 (large)
- Helped less than amisulpride group, an active treatment; not a sign of harm
How big was the difference?
2.62, large. The effect size compares Fluoxetine (Prozac) with amisulpride group.
See the 1 study
-
Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study. (2011)
- People in the study
- 40 randomised
- Dose
- 20 mg, uid
- Outcome
- SF-12 Short-Form 12-Item Health Survey
- Effect
- worse
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
Side effects
Stopping because of side effects2 studies
15% of patients in the fluoxetine group stopped treatment because of side-effects versus 4% of placebo-treated patients (table 1).
Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. (1996)All the subjects completed the planned 12-week long therapy period
Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study. (2011)
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
20 mg at the start in most studies
- 2Top dose
Most often 20 mg (4 of 4 studies)
Doses across 4 studies
20 to 20 mg.
Each study’s dose, as printed
- 20 mg, once a day Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. (1996)
- 20 mg, uid Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study. (2011)
- 20mg daily, for 10 weeks Pervasive refusal syndrome. (2012)
- 20 mg, once per day Clinical observation of moving cupping on the back for patients with chronic fatigue syndrome-related sleep disorders (2019)
All papers
- Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome.1996 · placebo trial · 107 randomised · 96 analysed
Summary
Researchers randomly assigned 107 patients with chronic fatigue syndrome to fluoxetine 20 mg once daily or placebo for 8 weeks; 96 completed the trial. Patients were randomly selected from a CFS database or referred by family doctors to the outpatient clinic of the Department of General Internal Medicine, University Hospital Nijmegen, and were divided into 48 depressed (9 men, 39 women) and 59 non-depressed (18 men, 41 women) patients. The study measured subjective fatigue, depression, psychological well-being, functional impairment, physical activity, sleep disturbances, neuropsychological functioning, social interactions, and cognitions. The paper reports no significant differences between fluoxetine and placebo in change during the 8-week treatment period for any dimension of CFS. Mean differences between fluoxetine and placebo in improvement in fatigue severity and depression severity were -0-164 (95% CI -0-64 to 0-31) and -0-186 (-0-35 to -0-02). No patient reported complete recovery. 15% of fluoxetine-treated patients stopped treatment because of side-effects versus 4% of placebo-treated patients. At the end of treatment, more fluoxetine-treated than placebo-treated patients complained of tremor (p=0-006) and perspiration (p=0-008). There was a trend for a drug effect on self-reported change at post-treatment (p=0-052), when patients from the fluoxetine group were more likely to report deterioration. The authors state that only patients who completed the trial were included in the analyses, and that they do not know whether a dose higher than the 20 mg daily may yield a better effect.
- Clinical observation of moving cupping on the back for patients with chronic fatigue syndrome-related sleep disorders2019 · randomised trial · 60 randomised
Summary
Objective: to observe moving cupping on the back for patients with chronic fatigue syndrome (CFS)-related sleep disorders. A total of 60 patients with CFS-related sleep disorders were randomized into a control group and an observation group, with 30 cases in each group. The control group received oral fluoxetine hydrochloride capsules, 20 mg once per day; the observation group received moving cupping on the back once every other day. Both were given for 4 weeks, with efficacy observed after 4 weeks of treatment. The fatigue scale-14 (FS-14) and Pittsburgh sleep quality index (PSQI) were assessed before and after treatment. The total effective rate was 93.3% in the observation group and 73.3% in the control group (χ2 =4.32, P=0.037). After treatment, physical fatigue, mental fatigue and total FS-14 scores in the observation group were lower than in the control group (all P<0.05). Subjective sleep quality, sleep latency, habitual sleep efficiency, use of sleeping medication, daytime dysfunction and total PSQI score improved more in the observation group than in the control group (all P<0.05); sleeping duration and sleep disturbances did not differ significantly between groups (both P>0.05). In the control group, sleeping duration, use of sleeping medication and total PSQI score decreased significantly (all P<0.05), while subjective sleep quality, sleep latency, habitual sleep efficiency, sleep disturbances and daytime dysfunction did not change significantly (all P>0.05). During treatment, 16 patients in the observation group took various sleeping medications; 20 patients in the control group took sleeping medication. The paper reports no drop-out case in any group during the trial and does not report side effects. The authors state limitations of a small sample size, a short treatment and observation period, and observation items that did not involve mechanism study.
- Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study.2011 · randomised trial · 40 randomised
Summary
This pilot study asked whether low-dose amisulpride would improve symptoms in non-depressed chronic fatigue syndrome (CFS) compared with an SSRI. Forty patients at a single centre, enrolled through clinician referrals and self-referrals, were randomised to amisulpride 25 mg bid. or fluoxetine 20 mg uid. for twelve weeks; all subjects completed the planned 12-week therapy period and were un-blinded to treatment. Fatigue (Krupp Fatigue Severity Scale, FSS), anxiety and depression (HADS), pain and bodily discomfort (VAS-pain), quality of life (SF-12) and clinician-rated severity (CGI-S) were assessed at enrolment and after twelve weeks; side effects were assessed with FIBSER at twelve weeks. After twelve weeks, amisulpride-treated patients had lower FSS scores (36.3 ± 8.6 vs. 48.9 ± 4.9; p = 0.001), lower VAS-pain scores (40.5 ± 13.1 vs. 53.1 ± 8.3; p = 0.01), higher SF-12 scores (53.2 ± 4.8 vs. 37.6 ± 4.9; p = 0.01) and lower CGI-S scores (2.9 ± 0.6 vs. 4.2 ± 1.1; p = 0.005) than fluoxetine-treated patients. HADS-D (4.1 ± 0.9 vs. 4.3 ± 0.9; p = 0.6) and HADS-A (4.5 ± 1.0 vs. 4.9 ± 1.0; p = 0.6) did not differ between groups. Within the amisulpride group, FSS, VAS-pain, CGI-S and SF-12 changed significantly (p = 0.001 for each), while HADS-A (p = 0.14) and HADS-D (p = 0.1) did not. Within the fluoxetine group, HADS-D fell significantly (p = 0.009); FSS (p = 0.1), VAS-pain (p = 0.09), CGI-S (p = 0.1), SF-12 (p = 0.1) and HADS-A (p = 0.8) did not change significantly. FIBSER frequency, intensity and burden did not differ between groups (p = 0.6, p = 0.9, p = 0.6), and both drugs were equally well tolerated.
- SSRI Use During Acute COVID-19 Infection Associated with Lower Risk of Long COVID Among Patients with Depression2024 · compared with another group · 506,903 with outcome data · preprint
- SSRI use during acute COVID-19 and risk of long COVID among patients with depression.2024 · compared with another group · 302,626 with outcome data
Summary
This retrospective cohort used N3C electronic health records from patients with a depressive disorder and acute SARS-CoV-2 infection. The text reports 302,626 patients; 100,803 (33%) were SSRI users and 201,823 (67%) were nonusers. Table 1 lists 101,016 SSRI users and 202,354 nonusers. SSRI use was defined as beginning at least 30 days before COVID-19 and continuing through acute COVID-19. SSRI users were compared with all other patients, defined as nonusers. The outcome was Long COVID (PASC) diagnosis by ICD code U09.9 between 1 and 12 months (day 31 to 365) after acute infection. SSRI users had a lower risk of Long COVID than nonusers (adjusted risk ratio 0.922, 95% CI 0.863 to 0.986). The unadjusted association was 1.042 (95% CI 0.984 to 1.104). New SSRI users also had a lower risk (adjusted risk ratio 0.886, 95% CI 0.780 to 0.985). For fluoxetine, sertraline, escitalopram, paroxetine, and citalopram, the study did not detect an association with Long COVID. No dose-response was found for fluoxetine 60 mg vs 10 mg (adjusted risk ratio 1.421, 95% CI 0.656 to 3.080). Harms, withdrawals, and people who worsened were not reported. The authors state limitations include binary time-invariant exposure, possible outcome misclassification, residual bias from observational design, and limited generalizability.
- On the question of infectious aetiologies for multiple sclerosis, schizophrenia and the chronic fatigue syndrome and their treatment with antibiotics.2009 · no comparison group
Summary
This paper reports an open clinical pilot study at a private out-patient clinic. Eight women and five men with psychotic symptoms entered between 2 March and 22 December 2006; two women with chronic fatigue syndrome were added in February and March 2007. There was no comparison group. The paper describes treatment with doxycycline 100 mg and clindamycine 300 mg twice daily for thirty days, and weekly multi vitamin B injections in case descriptions. On one year follow-up, six of the eight female patients showed excellent treatment results and two were rated as having had a significant improvement. Of the five men, two showed significant treatment results and three were rated as having had a slight to moderate improvement. The first patient with chronic fatigue syndrome showed excellent treatment results on follow-up one year later after sixty days of antibiotics; the second, who also took the combination for sixty days, was rated as having shown a significant improvement. The paper also describes a patient whose condition became much worse with fluoxetine (Prozac) 20 mg daily and another whose condition deteriorated with SSRI antidepressants. The paper does not report side effects, withdrawals, or stopping during the antibiotic treatment. The authors state that the promising results seem to warrant further and controlled clinical trials with treatment with antibiotics of patients with psychotic symptoms.
- Proceedings #19. Maintenance tDCS: A Case of Full and Durable Recovery from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)2017 · case report · 1 in the study
Summary
This conference proceeding reports a case report of one 61-year-old man with treatment-resistant progressive ME/CFS who was referred for neuromodulation. There was no comparison group. He was trained in the office and then self-administered tDCS at home daily, with anode on the left dorsolateral prefrontal cortex, cathode on the right dorsolateral prefrontal cortex, 2 mA/min, 20 minutes, 40 mA total dose, using 1.5” diameter electrode pads. After four weeks, sessions were increased to twice daily (6 AM and 12 Noon). Modafinil 200 mg provided partial relief of fatigue; later the dose was lowered to 100 mg due to insomnia, and modafinil was stopped but resumed at 100 mg daily after he felt less well. The paper reports one year of maintenance tDCS and follow-up neurophysiological studies 14 months after initial presentation. It reports significant benefit early in the day during the first month of daily tDCS, consistent benefit after twice-daily sessions, and full clinical recovery over the next few months, with improved exercise tolerance and a return to physical exercise several times each week. Before treatment, omission errors were 14.29%; after treatment, behavioral measures were within the normal rage and there were no omission errors. The patient reported sustained relief. The authors state that data were not shown for frontocentral infra-slow frequency drift.
- Pervasive refusal syndrome.2012 · case report · 1 in the study
- Recovery from chronic fatigue syndrome with modafinil.2004 · case report · 1 in the study
Summary
This case report describes one patient with CFS who first presented to his GP and was given a course of modafinil at a dose of 200 mcg mane. There was no comparison group, no randomisation, no blinding and no crossover. The report states that modafinil was successful in treating the patient's debilitating fatigue. Energy levels improved from 20% to 60% of optimum in the space of a few months. The patient was able to return to part-time work and to enjoy a good quality of life. The paper does not report harms, side effects or withdrawals; harms and withdrawals are not reported. It also does not report whether the patient stopped treatment or worsened. The report is a single case, so no between-group results are available. The authors state that whether patients with CFS would need to take modafinil long term needs to be established, and that long-term, double-blind, randomized controlled trials would be warranted to investigate efficacy and safety.
- Chronic parvovirus B19 infection resulting in chronic fatigue syndrome: case history and review.1997 · case report · 1 in the study
- Chinese herbal medicine for the treatment of chronic fatigue syndrome: A systematic review and meta-analysis.2022 · systematic review
Summary
This systematic review and meta-analysis asked whether Chinese herbal medicine (CHM) treats chronic fatigue syndrome. It included 84 RCTs with 6,944 participants; all studies were conducted in China. Participants received CHM formulas, alone or with Western conventional medicine, graded exercise therapy, or health guidance, and were compared with contrast groups that included Western conventional medicine, graded exercise therapy, health guidance, or placebo, for varying durations. The review measured FS-14, FAI, SCL-90, SAS, SDS, clinical symptom scores, IGA, IGG, IGM, NK cell levels, a clinical rate outcome, and adverse events. CHM decreased FS-14 scores (WMD: –1.77; 95%CI: –1.96 to –1.57; p < 0.001) and FAI scores (WMD: –15.75; 95%CI: –26.89 to –4.61; p < 0.01). It also decreased SCL-90, SAS, SDS, and clinical symptom scores and elevated IGA, IGG, and IGM. NK cell levels showed no significant difference between groups (WMD: 2.30; 95%CI: –0.47 to 5.07; p = 0.104); one study comparing CHM with placebo reported higher NK cell levels (WMD: 4.92; 95%CI: 2.27–7.57; p < 0.001). The clinical rate outcome was higher in the treatment group (RR = 1.41; 95%CI: 1.33–1.49; p < 0.001). Adverse events in the CHM group included mild nausea, dry mouth, indigestion, constipation, and fever; serious adverse events or deaths were not found, and two studies reported no adverse events. Worsening and stopping treatment were not reported. The authors state the reports were of poor quality and results should be interpreted cautiously, with methodological flaws, clinical heterogeneity, and all trials in China limiting the findings.
- What treatments work for anxiety and depression in children and adolescents with chronic fatigue syndrome? An updated systematic review.2022 · systematic review
Summary
This systematic review updated searches from 2015 to 2020 in Cochrane Library, Medline, Embase and PsycINFO for studies of children and adolescents with CFS/ME and validated measures of depression and/or anxiety. Combined with previous reviews, 16 studies and 965 participants were included; follow-up ranged from immediately post-treatment to 21 years. Treatments included CBT, the Lightning Process, valacyclovir, pacing, gammaglobulin, placebo, and inpatient or specialist care programmes. An RCT compared Lightning Process plus specialist medical care with specialist medical care alone; the review reports adjusted mean differences in depression and anxiety scores at 6 and 12 months, for example depression −1.5 (−3.5 to 0.5, 0.1) at 6 months and −1.8 (−3.4 to −0.1, 0.04) at 12 months. An observational cohort of routine specialist care measured depression and anxiety at baseline but not post-treatment. CBT-type interventions had most evidence for improving comorbid anxiety and/or depressive symptoms, but delivery and modality varied. A trial reported a deterioration in school attendance in the pacing arm. The review reports insufficient evidence to draw conclusions, and no study specifically targeted depression or anxiety. The authors state the evidence is poor and insufficient for meta-analysis.
- Acupuncture Treatment for Chronic Fatigue Syndrome2019 · systematic review
Summary
This chapter systematically reviewed acupuncture treatment for chronic fatigue syndrome (CFS) based on a broad literature search and the authors’ experiences. It reports 40 clinical research papers on acupuncture for CFS published over the last 10 years. The reviewed studies used simple acupuncture, electro-acupuncture, blood-letting acupuncture, acupoint application, acupoint catgut embedding, acupoint injection, auricular acupuncture, abdominal acupuncture, moxibustion, cupping and combined therapies. Examples include 32 CFS patients given acupuncture at acupoints versus non-meridian points, measured with the WHOQOL-BREF; 60 cases randomly divided into electro-acupuncture on acupoints or non-acupoints, 30 cases in each group, measured with FSS, SPHERE, VAS and SF-36, with the acupoints group reported better (P < 0.01); and 180 CFS patients randomly divided into 2 groups (92 treatment, 88 control) for acupoint injection. Reported rates included a total effective rate of 93.75% for electro-acupuncture plus auricular application, a total efficiency of 96.7% for auricular acupuncture in 60 cases, and a total efficiency of 94.34% for abdominal acupuncture. A reviewed RCT found no obvious difference between a low sugar low yeast diet and healthy eating. The harms text states auricular acupuncture with acupoint catgut embedding has fewer clinical side effects than traditional acupuncture, while excessive exercise may lead to immune function disorders and may aggravate CFS symptoms. Numbers who worsened or stopped were not reported. The authors state current research lacks a unified syndrome differentiation standard and a unified evaluation standard of efficacy.
- What treatments work for anxiety in children with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)? Systematic review.2017 · systematic review
Summary
This systematic review asked what treatments work for anxiety in children with CFS/ME. The authors searched Medline, Embase and psychINFO in July 2016 and included nine papers from eight studies of children under 18 years with CFS/ME and a valid anxiety assessment. None targeted anxiety as a primary outcome; six treatment studies measured anxiety as a secondary outcome. Four used CBT-type approaches, one a behavioural approach, and one compared intravenous gammaglobulin with placebo. Sample sizes ranged from 1 to 135. In Chalder et al, 23 participants (18 at follow-up) received a CBT-based rehabilitation programme; anxiety improved significantly at 6 months, and the 20 participants who completed treatment returned to school, with 19 of 20 attending full time. Lloyd et al enrolled 63 participants in telephone CBT; anxiety improved significantly (treatment effect estimate −0.49, p=0.003), school attendance improved from 24% to 49%, and fatigue reduction was not significant. Nijhof et al randomised 135 (112 at long-term follow-up) to FITNET internet-delivered CBT or usual care; full school attendance was 50 (75%) vs 10 (16%), and 63% were defined as recovered compared with 8%. Wright et al randomised 13 (11 at follow-up) to STAIRway or pacing; the anxiety difference was −1.60, p=0.6, and school attendance deteriorated in the pacing arm. Rowe et al recruited 71 (70 at follow-up) to gammaglobulin or placebo; anxiety reduced in both arms. The authors state insufficient evidence to conclude the best treatment.
- Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop.2015 · systematic review
Summary
This systematic review examined treatments for adults with ME/CFS. It included 35 treatment trials in 45 publications; trials enrolled predominantly middle-aged women from ME/CFS specialty clinics and used CFS case definitions. Treatments were compared with placebo, usual care, wait-list, relaxation, adaptive pacing, CBT, or other therapies. In 2 fair-quality trials (n=324), rintatolimod improved cardiopulmonary exercise test tolerance (36.5% versus 15.2%; P=0.047), exercise duration (10.3% versus 2.1%; P=0.007), and exercise work (11.8% versus 5.8%; P=0.01). In a small trial of 30 participants, valganciclovir improved fatigue on 1 scale but showed no statistically significant differences for other measures. Trials of galantamine, hydrocortisone, IgG, isoprinosine, and fluoxetine indicated no beneficial effects but were limited by small numbers. Counseling and behavior therapies improved fatigue, function, quality of life, work impairment, and global improvement in some trials (low to moderate strength of evidence). A meta-analysis of 4 CBT trials found no statistically significant difference in SF-36 physical function (weighted mean difference, 10.42 [95% Cl, -3.86 to 24.69]); a sensitivity analysis found 6.02 [Cl, 1.05 to 10.88]. GET improved function (10.68 [Cl, 6.32 to 16.88]), fatigue (4 trials, n=619), and global improvement (relative risk, 1.58 [Cl, 1.24 to 2.47]). In the PACE trial, deterioration of physical function was 25% with adaptive pacing, 18% with usual care, and 11% with GET (P<0.001). Harms included galantamine: 90% reported harms and 2% serious events, none attributed to study drug; IgG headaches 93% versus 60%; GET serious adverse events 17 versus 7. GET withdrawals were 37% versus 22%, and 20% declined repeat exercise testing. Adverse effects were rarely reported overall.
- Traditional Chinese medicine for chronic fatigue syndrome: a systematic review of randomized clinical trials.2014 · systematic review
Summary
This systematic review asked whether traditional Chinese medicine (TCM) helps chronic fatigue syndrome (CFS). It included 23 RCTs involving 1776 participants. The trials tested Chinese herbal medicine, acupuncture, electroacupuncture, moxibustion, acupoint application, qigong and combined treatments. Comparators were non-specific treatment, sham-acupuncture, sham-electroacupuncture, Fluoxetine, hydrocortisone, placebo, no treatment or paroxetine alone. Fatigue was measured with several scales. A meta-analysis of five studies favored Chinese herbal medicine over non-specific treatment on GPFS (MD −5.93 [−7.51, −4.34]). Individual studies also favored Chinese herbal medicine on CFS1 total FS score (MD −1.51 [−2.40, −0.62] and MD −3.90 [−5.05, −2.75]) and CFS2 plus auxiliary symptom score (MD −29.76 [−35.55, −23.97]). Acupuncture was favored in two meta-analyses and three individual studies; pooled CFS1-total FS score was 2.61 lower (3.56—1.65 lower) in 261 participants from 4 studies. Two individual studies found no significant difference between acupuncture and sham-acupuncture for CFS1-mental FS score and CFS2-physical FS score. Electroacupuncture, moxibustion, acupoint application, qigong and combined treatments also showed favoring results. Quality of life findings were inconsistent. Studies 20, 22 and 28 reported mild and transient adverse events such as nausea, thirst or bleeding due to acupuncture. The authors state TCM appears to alleviate fatigue, but risk of bias was high and larger studies are needed.
- Complementary and alternative medicine for patients with chronic fatigue syndrome: a systematic review.2011 · systematic review
Summary
This systematic review examined randomised controlled trials of complementary and alternative medicine (CAM) for patients with chronic fatigue syndrome (CFS), also termed myalgic encephalomyelitis (ME). The search was up to 13th August 2011. A total of 26 RCTs, which included 3,273 participants, met the inclusion criteria. The CAM therapies included mind-body medicine, distant healing, massage, tuina and tai chi, homeopathy, ginseng, and dietary supplementation. The review reports that studies of qigong, massage and tuina demonstrated positive effects, whereas distant healing failed to show a significant effect on mental or physical components of quality of life. Compared with placebo, homeopathy had insufficient evidence of symptom improvement in CFS. Most supplements failed to show beneficial effects for CFS, with the exception of NADH and magnesium. Five of the 26 included studies reported no adverse events or a slight occurrence of them, and the other included studies lacked descriptions regarding adverse events; no severe adverse effects of CAM were noted. The authors state that firm conclusions are difficult with the limited number of RCTs for each therapy, small sample sizes and high risk of bias.
- Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic review.2006 · systematic review
Summary
This updated systematic review asked whether any intervention is effective for treatment, management or rehabilitation of adults and children with CFS/ME. The authors searched eleven electronic databases and included 70 studies, of which 59 were RCTs; comparisons were between treatment and control groups. Interventions included CBT, GET, rehabilitation, immunological and pharmacological treatments, supplements and complementary therapies. Outcomes covered physical, psychological, laboratory/physiological and quality-of-life measures. CBT and GET appeared to reduce symptoms and improve function based on RCTs. In a CBT trial (n=69), physical functioning, fatigue and symptoms favoured CBT (P<0.003) and school attendance favoured treatment (P=0.04). Another CBT trial (n=65) found no significant difference for fatigue, anxiety and depression, or disability. In GET trials, CGI and fatigue favoured treatment (n=49; P<0.03), and fatigue and depression/anxiety were significantly better (n=61; P=0.027). One GET trial reported withdrawal of one patient in each group because of worsening symptoms; eleven patients withdrew because of adverse events in a GET with or without fluoxetine trial. Galantamine (n=434) showed no significant differences; 130 patients withdrew, 389 reported adverse events and 88 withdrew. Acetyl-L-carnitine and propionyl-L-carnitine (n=90) improved general fatigue in PLC (P=0.004) and combined group (P<0.001), and mental fatigue in ALC group (P=0.015); 8 patients withdrew due to side effects. Staphylococcus toxoid (n=98) had 13 treatment-group and 7 placebo-group patients with side effects. Hydrocortisone/fludrocortisone (n=80) found no significant differences.
- Exercise therapy for chronic fatigue syndrome.2004 · systematic review
Summary
This systematic review asked whether exercise therapy is more effective than control treatments for chronic fatigue syndrome. Five included randomised studies randomised 336 participants in the United Kingdom, Australia, and New Zealand. Exercise therapy was aerobic graded exercise lasting 12 weeks. Comparators were treatment as usual, relaxation plus flexibility, fluoxetine, exercise plus fluoxetine, and exercise plus patient education. Outcomes included the Chalder Fatigue Scale, depression, quality of life, sleep, functional work capacity, and drop-out. At 12 weeks, those receiving exercise therapy were less fatigued than control participants (SMD -0.77, 95% CIs -1.26 to -0.28); at 24 weeks the difference was not significant (SMD -1.04, 95% CIs -2.49 to 0.40). Physical functioning improved with exercise therapy (SMD -0.64, CIs -0.96 to -0.33). Depression was non-significantly improved at 12 weeks (WMD -0.58, 95% CIs -2.08 to 0.92). Participants receiving exercise therapy were less fatigued than those receiving fluoxetine at 12 weeks (WMD -1.24, 95% CIs -5.31 to 2.83). Those receiving exercise plus fluoxetine were less fatigued than those receiving exercise alone at 12 weeks, but the difference did not reach significance (WMD 3.74, 95% CIs -2.16 to 9.64). Exercise plus patient education was less fatigued than exercise alone (WMD 0.70, 95% CIs -1.48 to 2.88). Drop-out was more common with exercise therapy (23/161) than control (13/154; RR 1.73, 95% CIs 0.92 to 3.24), although not significant. No adverse-effect data were reported. The authors stated that the main limitation was the lack of evidence with which to inform results and conclusions.
- Interventions for the treatment and management of chronic fatigue syndrome: a systematic review.2001 · systematic review
Summary
This systematic review asked whether interventions for chronic fatigue syndrome (CFS) work. Nineteen specialist databases were searched, and 44 trials met inclusion criteria: 36 randomized controlled trials and 8 controlled trials. Treatments were grouped by type and compared with control conditions. Outcomes were classified as positive, negative, or no effect. Three randomized controlled trials of GET all showed an overall beneficial effect compared with control groups. Three of four randomized controlled trials of CBT found a positive overall effect; one controlled trial did not find overall beneficial effects. One randomized controlled trial found no effect of fluoxetine either alone or with GET. Hydrocortisone showed an overall beneficial effect in one randomized controlled trial and some beneficial effects in another. For immunoglobulin, two randomized controlled trials showed an overall beneficial effect, two showed some positive effects, and the largest reported no effect. Acyclovir showed a negative effect for one outcome. Randomized controlled trials of fludrocortisone, antidepressants, moclobemide, sulbutiamine, growth hormone and galanthamine hydrobromide found no effects. Oral NADH showed an overall beneficial effect in one randomized controlled trial. Harms included withdrawals from immunoglobulin therapy (2 due to severe constitutional symptoms, 1 due to a skin eruption, 1 due to mild but transient liver failure, 1 due to phlebitis, and 2 whose adverse effects were not reported), 3 withdrawals from acyclovir due to reversible renal failure, and 2 participants leaving the magnesium group after a generalized rash. CBT trials had a dropout rate of 19% (114/589), GET trials 18% (68/370), and pharmacological trials 11% (99/869).
- Using Tai Chi and Qigong to Treat Chronic Fatigue Syndrome: An Application of Artificial Intelligence to Traditional Chinese Medicine2026 · review
Summary
AI-assisted review of fourteen English-language publications identified via PubMed summarized Tai Chi and Qigong for CFS/ME: 5 completed randomized controlled trials, 3 study protocols, 3 systematic reviews/meta-analyses, 2 non-randomized interventions and 1 case series. Findings were reported study by study, not as a pooled review result. Dybwad (2007; 31 participants) reported Qigong improved work capacity (VO2max, p=0.01) and fatigue severity (p<0.05) vs no treatment, with no significant SF-36 differences. Chan et al. (2017; 108 females: 46 Qigong, 62 waitlist) reported increased adiponectin (median change 0.8 vs -0.1 mg/L, p<0.05) and lower anxiety (median 7.0 vs 10.0, p<0.05) and depression (median 5.0 vs 7.0, p<0.05; change -4.0 vs -1.0, p<0.001). Ho et al. (2012; 64 participants: 33 Qigong, 31 control) reported fatigue reduction (F=12.93, p<0.05, d=-1.5 to -2.1) and telomerase increase (0.102 to 0.178, p=0.033, d=0.52, F=5.03, p<0.05). Kong et al. (2023; 1,187 participants) reported fatigue SMD=0.85 (95% CI 0.64–1.07, I2=54%) vs passive controls and 0.08 (-0.18–0.34, I2=0%) vs active controls. Ho et al. reported no adverse effects; Kong et al. reported minor AEs; Wang et al. (2014; 1,776 participants) reported no serious AEs. Worsening and stopping were not reported. The authors state methodological limitations.
- Antidepressants for prevention of severe COVID-19, Long COVID and outlook for other viral diseases2024 · review
Summary
This paper is an Opinion review, not a primary study; it reports no own participants, location, treatment duration, or primary outcome. It summarizes literature found in pubmed as of 09/25/2023: five prospective studies (plus 2 for Long COVID), 7 RCT (plus 2 for Long COVID) and 12 meta-analyses. The review discusses antidepressants for prevention of severe COVID-19 and Long COVID. In its Long COVID table, named entries include fluvoxamine (2 × 50 mg) for Bramante et al. 2022, marked 0; fluoxetine for Farahani et al. 2023, marked (+) Fluoxetine (Fatigue); vortioxetine for Di Nicola et al. 2023, marked +; tricyclic AD for La Sala et al. 2023, marked + Tricyclic AD (2 Cases); AD for Fontera et al. 2022, marked +; SSRI for Rus et al. 2023 (N = 95), marked +; and SSRI for Sidky et al. 2023 (N = 17,933; preprint), marked +. For harms, the review states tolerability of AD was reported to be generally well across prospective, randomized controlled studies and meta-analyses presented in the table. Siripongboonsitti et al. 2023 is noted with no deaths in both the fluvoxamine and control group. The authors describe Long COVID evidence as limited but with first preliminary promising results for AD. The paper itself does not compare arms; it tabulates named studies, including placebo-controlled randomized studies. The recorded data do not report people who worsened or stopped.
- Advances in Clinical Research on Traditional Chinese Medicine Treatment of Chronic Fatigue Syndrome.2020 · review
Summary
This review summarized clinical research on traditional Chinese medicine for chronic fatigue syndrome (CFS), described as CFS or myositis encephalomyelitis (ME). The authors searched PubMed, Web of Science, JAMA Network, CNKI, SinoMed and WanFang Data (2010~2020.3 and 2015~2020.3) and included 77 articles, 20 in English and 57 in Chinese. The reviewed treatments included herbal decoctions and proprietary Chinese medicines, moxibustion, acupuncture, tuina, cupping, and combinations of these. Many summarized studies reported higher total effective rates in observation groups than in control groups; the review did not pool these into a single comparison. Adverse drug reactions were mentioned for an estradiol patch study, without counts. The authors state that exact efficacy is still controversial. They report that diagnostic criteria, treatment methods and efficacy evaluations lack consensus, that repeated experiments were lacking, and that the level of evidence is not good enough.
- Graded exercise therapy does not restore the ability to work in ME/CFS - Rethinking of a Cochrane review.2020 · review
Summary
This review examined the amended Cochrane exercise review and the eight randomised controlled trials it included, with data from 1518 participants with ME/CFS from all diagnostic criteria. The treatments compared were exercise therapy versus no-treatment, relaxation and flexibility, or adaptive pacing. Outcomes included fatigue, physical functioning, objective exercise measures, quality of life, symptom count, and work. The review reports that exercise therapy probably reduces fatigue by 3.4 points on the Chalder fatigue scale (0 to 33) compared with no-treatment or relaxation and flexibility after 12 to 26 weeks; the effect after 52 to 70 weeks is uncertain. Physical functioning may moderately improve after 12 to 24 weeks (low evidence), and the effect after 52 to 70 weeks is uncertain; compared with adaptive pacing, exercise therapy may slightly improve physical functioning after 24 and 52 weeks. The authors report that objective outcomes in most included studies showed no objective improvement. In PACE (n = 640), 6MWT was 35.3 for no-treatment, GET had no effect on fitness, and symptom count did not differ significantly between GET and SMC (p = 0.0916) or GET and APT (p = 0.23). In an Oxford Brookes survey (n = 2,274), worsening after treatment was reported by 81.1% for GET, 85.9% for GET combined with CBT, and 58.3% for CBT combined with GET. In Wearden et al. (1998), 34.3% (23/67) complied fully with graded exercise versus 78.3% (54 of the 69 patients) with exercise placebo.
- Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: all roads lead to Rome.2017 · review
Summary
This comprehensive review examines benefits and harms of treatments for CFS/ME and makes recommendations. It reports no single enrolled or analysed total. Among the included studies, a phase II rintatolimod trial had 92 patients and a phase III trial had 234 patients; a rituximab RCT had 30 patients, with sustained overall improvement in 67% of CFS/ME patients versus 13% of controls. The PACE trial had 640 patients; a recovery paper reported 22% recovered in the CBT and GET groups, compared with 8% in the APT group and 7% in the SMC-only group. A survey of 828 Norwegian CFS subjects reported pacing useful in 96%, and 79% of patients with experience of graded training considered it worsened their health. CoQ10 plus NADH was studied in 80 patients, with maximum heart rate p=0.022. The review also describes harms: three patients administered acyclovir withdrew due to reversible renal failure, and two out of 13 participants developed neutropenia. The authors state no firm conclusions can be drawn because the few RCTs were small-scale, with a high risk of bias, and used different case definitions; nutritional studies were very limited, mostly small and without long-term follow-up.
- Treating chronic fatigue syndrome - a study into the scientific evidence for pharmacological treatments.2011 · review
Summary
The paper reports a questionnaire survey of 94 CFS patients from Queensland and New South Wales, recruited through support groups and newspaper and email advertisements, plus a search for randomised controlled trials. Patients filled out a questionnaire on current medicines and supplements; no treatment was given by the authors, and the survey had no comparison group. The 94 patients used 474 different medicines and supplements. Commonly used were antidepressants (41%), sedatives (27%), B vitamins (47%), magnesium (24%) and co-enzyme Q10 (7%). The search identified 20 RCTs. Findings included no difference for fluoxetine on fatigue or SF-36, no difference between treatment and placebo on individual questionnaires, and no effect for several agents including phenelzine, moclobemide, valaciclovir, terfenadine, melatonin, ginseng, bovine liver extract and a polynutrient supplement. One hydrocortisone trial reported 87% rated themselves improved versus 17% on placebo (p<0.001); another reported 53% vs. 29% (p=0.04) improvement in wellness score. Harm notes included diarrhoea with high-dose oral magnesium, long-term adrenal gland suppression with adrenal hormones, addiction and loss of effectiveness with benzodiazepines and opiates, and hormonal/lipid changes with DHEA. No worsening or stopping was reported. The authors state limitations.
- Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants.2009 · review
Summary
This review did not run its own trial; it summarized published data on pharmacological treatment of chronic fatigue syndrome (CFS), identified through a PubMed literature search. The review covers antidepressants and other psychotropic agents in CFS. In included randomized, placebo-controlled trials, moclobemide vs. placebo (47 vs. 43) showed clinically global improvement 51 vs. 33% (OR = 2.16); KPI mean difference between two groups was 0.28 favoring MCB, and Vigor subscale on POMS mean difference was 0.51 favoring MCB. Overall response by subjective global impression was 51% with moclobemide vs. 23% with placebo. At 12 weeks, MIR failed to separate from PBO on FS; at 24 weeks, CBT + MIR showed significantly more reduction in FS scores than PBO + CBT, with an observed difference of 5.5 (95% CI = 15.4 – 22), whereas MIR + CBT failed to separate from PBO + CBT. Fluoxetine failed to separate from PBO on SFS and BDI scores, and failed to demonstrate benefit on listed outcome measures. The review lists harms: TCAs potentially induce sedation and orthostatic hypotension; MAOIs have hypertensive crisis; stimulant medications carry risks of misuse, abuse, withdrawal, and diversion. Authors state research does not support definitive conclusions about antidepressant efficacy in CFS.
- Antidepressants and cognitive-behavioral therapy for symptom syndromes.2006 · review
Summary
This review article examined antidepressant medications and cognitive-behavioral therapy for 11 somatic syndromes, including chronic fatigue syndrome. It did not report its own enrolments, analysed patients, setting, or follow-up; patient counts were not reported. The review described trials of antidepressants versus placebo and trials of CBT. Outcomes included global symptoms, pain, sleep, fatigue, mood, and energy. For CFS, the review reports that a systematic review found two interventions beneficial for improving but not curing symptoms: CBT and graded exercise. It reports that six of the seven RCTs of CBT on CFS found benefit, with an effect lasting for 5 years. Among antidepressant trials, two fluoxetine trials showed no benefit other than for depressive symptoms; one phenelzine trial showed improvement in multiple CFS symptoms, illness severity, and mood; and a moclobemide trial showed improvement in subjective vigor and energy. The review reports mixed evidence that antidepressants lead to overall improvement and states there is no randomized trial evidence demonstrating any efficacy for methylphenidate. The authors state that evidence for antidepressants in CFS is limited and insufficient for convincing conclusions.
- Chronic fatigue syndrome: traditional and community-based approaches to rehabilitation.2004 · review
Summary
This narrative review summarised and critically reviewed existing studies of psychological and psychosocial rehabilitation for chronic fatigue syndrome (CFS), searching Medline, PSYCHINFO, CINAHAL, ERIC and the Science Citation Index. Reviewed treatments included CBT with graded activity, graded exercise, activity pacing, supportive counselling, multidisciplinary inpatient and community-based programmes. Sharpe et al. 1996 reported 73% CBT achieved satisfactory outcome vs. 27% usual care, 73% vs. 23% improved function by >10 points, and 63% vs. 20% improved work status. Fulcher & White 1997 reported 51% in the exercise group improved vs. 27% of controls. Wearden et al. 1998 reported exercise improved fatigue and functional work capacity at 12 and 26 weeks; fluoxetine improved depression at 12 weeks, not sustained at 26 weeks. Powell et al. 2001 reported all three intervention groups improved more than controls at one-year follow-up. Ridsdale et al. 2001 found no differences between CBT and counselling at 3 and 6 months; 53% of the original sample were fatigue cases at 6 months. Marlin et al. 1998 reported 61% returned to gainful employment, 27% functioned at a level equivalent to employment, and 12% remained on disability. Dropout rates included 42% in exercise + fluoxetine, 38% CBT in Prins et al. 2001, and 36% cognitive therapy in Ridsdale et al. 2001. The authors state current evidence for complete and enduring benefit of any single approach remains relatively weak, and many studies are limited by absence of a placebo control group, high dropout rates and selection bias.
- Chronic fatigue syndrome in the psychiatric practice.2002 · review
Summary
This REVIEW ARTICLE concerns chronic fatigue syndrome (CFS) and reviews treatments for CFS, reporting cited trials rather than a new study. Vercoulen contrasted fluoxetine with placebo in 96 patients and did not find any significant effect on fatigue complaints or depression complaints. Wearden examined fluoxetine, placebo and physical exercise in 136 patients; fluoxetine gave a significant improvement of depression scores but a non-significant improvement of fatigue complaints, while physical exercise appeared to result in a significant improvement of fatigue complaints. Natelson studied phenelzine against placebo in 24 patients and found an improvement of fatigue complaints compared with placebo. Behan found a superior antidepressant effect of sertraline vs clomipramine in 40 patients, with no placebo group. Deale reported at final follow-up that 70% of the CBT group achieved a substantial improvement in physical functioning, compared with 19% of the relaxation group. Reference 38 found the number of patients showing clinical improvement was not significantly higher with hydrocortisone than with placebo; reference 39 showed a significant reduction in self-reported fatigue scores with hydrocortisone compared with placebo. Higher doses of cortisone in one study caused adrenal suppression in 40% of patients participating in active treatment. The authors conclude that antidepressants do not seem to have a positive influence on fatigue but appear beneficial for depression and social functioning; CBT and graded exercise show significant improvement and are the only treatments available for CFS patients; glucocorticoid therapy is not recommendable as a standard treatment. Limitations are not reported.
- Chronic fatigue syndrome and fibromyalgia: clinical assessment and treatment.2001 · review
Summary
This review examined treatment literature for chronic fatigue syndrome (CFS) and fibromyalgia (FM); it did not report its own enrolled participants, setting, or follow-up. It described studies of Ampligen, antidepressants (fluoxetine, amitryptaline), NADH, massage, essential fatty acids, cognitive-behavioral treatment (CBT) and graded activity-oriented CBT (GA/CBT), graded exercise, pacing/envelope theory, and other alternative or interdisciplinary approaches. Duration was reported only for GA/CBT trials: 13 to 16 sessions. Many cited trials had controlled, randomized, or crossover designs, but the review gave no single pooled comparison. In cited studies, fluoxetine had no effect on CFS or depression symptoms in one controlled study and only a temporary effect on depression symptoms in another; a later essential-fatty-acid trial failed to replicate earlier findings; and NSAIDs were not significantly associated with improved outcomes in a meta-analysis of 49 FM treatment studies. About one-third of patients responded favorably to NADH with at least 10% improvement in symptom scores. CFS patient ratings ranked antiallergy/antiyeast diets and biofeedback/stress management at 24–30% favorable to highly favorable. The review notes Ampligen reports of poor outcomes and adverse reactions, states drug hypersensitivity and adverse reactions are not uncommon, and says GA/CBT may trigger symptom flareups in clients without fear-based avoidance. It states that clinical-study participants are usually from tertiary care centers, so representativeness is unclear, and that controversy over theory-driven CBT for CFS remains unresolved. It also states low-level exercise should be discontinued if it worsens symptoms.
- Chronic fatigue syndrome.2000 · review
Summary
Clinical review searched January 1999 for randomised controlled trials of treatments for chronic fatigue syndrome. It assessed antidepressants, corticosteroids, exercise, prolonged rest, dietary supplements, immunotherapy, cognitive behavioural therapy, and oral nicotinamide adenine dinucleotide. In antidepressants, one RCT compared fluoxetine with placebo in 96 people and found no significant benefit; another allocated 136 people to exercise plus fluoxetine, exercise plus placebo, appointments plus fluoxetine, or appointments plus placebo and found no significant difference in fatigue. In corticosteroids, a trial in 32 people found nine people (28%) taking hydrocortisone improved compared with three (9%) taking placebo; a 65-person hydrocortisone trial found greater improvement on a self-rated wellness scale but other self-rating scales did not show significant benefit. In exercise, an RCT in 66 people reported 55% of the aerobic exercise group much better or very much better compared with 27% of the flexibility training group; a 136-person trial found exercise associated with significant improvements in fatigue and functional work capacity. CBT trials: in 60 people, 73% receiving CBT improved compared with 27% receiving standard care; in another 60 people, 63% had a good outcome with CBT compared with 17% with relaxation therapy. An IgG trial randomised 49 patients; ten of 23 immunoglobulin recipients improved compared with three of 26 placebo recipients. An NADH crossover trial had 33 completers and 26 analysed; 8/26 attained a 10% improvement compared with 2/26 on placebo. Harms included up to 15% withdrawing from active antidepressant treatment because of adverse drug effects, and IgG adverse effects in up to 82% of trial participants.
- Randomised, double-blind, placebo-controlled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome.1998 · lab study · 136 in the study
Summary
This six-month randomised, placebo- and therapist-contact-controlled trial asked whether graded exercise and fluoxetine treat chronic fatigue syndrome. It enrolled 136 patients from consecutive referrals to a university department of medicine out-patient clinic across north-west England and north Wales between June 1993 and March 1995. Patients were allocated to exercise plus 20 mg fluoxetine (33), exercise plus placebo drug (34), exercise control plus 20 mg fluoxetine (35), or exercise control plus placebo drug (34). Graded exercise was 20 minutes at least three times per week; fluoxetine was a fixed daily 20 mg dose; all attended the hospital on eight occasions at weeks 0, 1, 2, 4, 8, 12, 20 and 26. Outcomes included fatigue scale, MOS scales, HAD scales and functional work capacity at weeks 12 and 26. Exercise resulted in fewer patients with case level fatigue than appointments only at 26 weeks (12 (18%) v. 4 (6%) P=0.025) and improved functional work capacity at week 12 (mean change 2.0, 95% CI 0.60-3.49; P=O.OOS) and week 26 (mean change 1.9, 95% CI 0.15-3.69; P=0.03). Fluoxetine had no effect on the fatigue scale at week 12 or week 26 and no significant effect on functional work capacity; it significantly reduced the HAD depression score at week 12 (P=0.04) but not at week 26 (P=0.28). Eleven subjects dropped out because of medication side-effects (two taking placebo drug); drop-out was greater with exercise than non-exercise (25/68 (37%) v. 15/69 (22%)), while fluoxetine (24/68 (36%)) versus placebo drug (16/69 (24%)) did not reach significance.
- A double-blind placebo controlled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome (CFS)1996 · lab study · 136 in the study
Summary
This six-month prospective randomised trial allocated 136 patients meeting Oxford research criteria for CFS, recruited from a University department of medicine outpatient clinic, to four treatment cells: exercise and fluoxetine; exercise and placebo drug; appointments and fluoxetine; appointments and placebo drug. Fluoxetine was given at 20 mg/day; graded exercise was delivered by a physiotherapist. The drug treatment was double-blind, and patients were blind to the exercise programme. The study tested efficacy and acceptability of these treatments for CFS patients with or without DSM-IIIR depressive disorders. Outcomes included fatigue, functional work capacity, health perception, completion, and full recovery from fatigue symptoms. Ninety (66%) patients completed the trial, and patients were more likely to drop out of exercise than non-exercise treatment (p = 0.05). There was a non-specific treatment effect on most measures. When patients complied fully with exercise, exercise had a significant effect on fatigue (p = 0.04), functional work capacity (p < 0.00 I) and health perception (p = 0.03). In patients who complied, fluoxetine had a significant effect on fatigue (p = 0.02). On intention to treat, 12 (18%) patients in the exercise groups had fully recovered from their fatigue symptoms at six months compared with four (6%) who did not receive exercise (p = 0.004). Significant improvement with exercise only occurred in patients with DSM-IIIR depressive disorders who were prescribed fluoxetine. Side-effect counts and stated limitations were not reported in the available text.